Low molecular weight heparin (reviparin) in percutaneous transluminal coronary angioplasty. Results of a randomized, double-blind, unfractionated heparin and placebo-controlled, multicenter trial (REDUCE trial)

Journal of the American College of Cardiology

Volumn 28, Issue 6, 1996, Pages 1437-1443

  Karsch, Karl R ^a   Preisack, Melitta B ^a   Baildon, Rainer ^a   Eschenfelder, Volker ^a   Foley, David ^b   Garcia, Eulogio J ^c   Kaltenbach, Martin ^d   Meisner, Christoph ^a   Selbmann, Hans K ^a   Serruys, Patrick W ^e   Shiu, Man F ^f   Sujatta, Martin ^a   Bonan, Raoul ^g  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b CARDIALYSIS   (Netherlands)

^c HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e ERASMUS MEDICAL CENTER   (Netherlands)

^f WALSGRAVE HOSPITAL   (United Kingdom)

^g MONTREAL HEART INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; REVIPARIN;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTICOAGULANTS; CORONARY ANGIOGRAPHY; CORONARY DISEASE; CORONARY VESSELS; DOUBLE-BLIND METHOD; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MUSCLE, SMOOTH, VASCULAR; PROSPECTIVE STUDIES; RECURRENCE;

EID: 0842348386     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(96)00343-9     Document Type: Article

References (42)

1. 1. Grüntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronary artery stenosis. N Engl J Med 1979;301:61-8.
2. 2. Holmes DR Jr, Vliestra RE, Schmith HC, et al. Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute, Am J Cardiol 1984;53:77C-81C.
3. 3. Detre K, Holubkov R, Kelsey S, et al., Co-Investigators of the NHLBI PTCA Registry. One-year follow-up results of the 1985-1986 National Heart, Lung, and Blood Institute's Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 1989;80:421-8.
4. 4. Leimgruber PP, Roubin GS, Hollman J, et al. Restenosis after successful coronary angioplasty in patients with single-vessel disease. Circulation 1986;68:710-7.
5. 5. Guiteras VP, Bourassa MG, David PR. et al. Restenosis after successful percutaneous coronary angioplasty: the Montreal Heart Institute experience. Am J Cardiol 1987;60:50-8.
6. 6. Ueda M, Becker AE, Fujimoto T, Tsukada T. The early phenomena of restenosis following percutaneous transluminal coronary angioplasty. Eur Heart J 1991; 12:937-45.
7. 7. Block PC. Restenosis after percutaneous transluminal coronary angioplasty: anatomic and pathophysiological mechanism - strategies for prevention. Circulation 1990;81 Suppl IV:IV-2-4.
8. 8. Hanke H, Strohschneider T, Oberhoff M, Betz E, Karsch KR. Time course of smooth muscle cell proliferation in the intima and media of arteries following experimental angioplasty. Circ Res 1990;67:651-9.
9. 9. Reidy MA, Walker LN. Endothelian-smooth muscle cell interaction in vivo. In: Strandness D, Didisheim P, Clowes A, Watson J, editors. Vascular Disease. Orlando (FL): Grune & Stratton, 1987:185-95.
10. 10. Clowes AW, Clowes MM, Reidy MA. Kinetics of cellular proliferation after arterial injury. I. Smooth muscle growth in the absence of endothelium. Lab Invest 1983;49:327-33.
11. 11. Finci L, Meier B, Roy P, Steffenino A, Rutishauser W. Clinical experience with the Monorail balloon catheter for coronary angioplasty. Cathet Cardiovasc Diagn 1988;14:206-12.
12. 12. Dimas AP, Grigera F, Arora RR. Repeat coronary angioplasty as treatment for restenosis. J Am Coll Cardiol 1992;19:1310.
13. 13. MacDonalds RG, Barbieri E, Feldman RL, Pepine CJ. Angiographic morphology of restenosis after percutaneous transluminal coronary angioplasty. Am J Cardiol 1987;60:50-4.
14. 14. Serruys PW, Luijten HE, Beutt KJ. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon: a quantitative angiographic follow-up study in 342 patients at 1, 2, 3, and 4 months. Circulation 1988;77:361-71.
15. 15. Hirsh J. Heparin. N Engl J Med 1991;324:1565-74.
16. 16. Hirsh J, Fuster V. Guide to anticoagulant therapy. I. Heparin. Circulation 1994;89:1449-68.
17. 17. Boneu B. An international multicenter study: reviparin in the prevention of venous thromboembolism in patients undergoing general surgery. Blood Coagulation Fibrinolysis 1993;4:S21-2.
18. 18. Planes A, Chastang C, Vochelle N, Desmichels D, Alach M, Fiessinger JN. Comparison of antithrombotic efficacy and haemorrhagic side-effects of reviparin-sodium versus enoxiparin in patients undergoing total hip replacement. Blood Coagulation Fibrinolysis 1993;4:S33-5.
19. 19. Roth D, Betz E. Kultivierte Gefässwandzellen des Menschen. Ein Modell zur Aufklärung potentiell antiarterioskelrotisch wirkender Substanzen. Vasa 1992;35 Suppl:125-7.
20. 20. Hanke H, Oberhoff M, Hanke S, et al. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular weight heparin. Circulation 1992;85:1548-56.
21. 21. Schmid KM, Preisack MB, Voelker W, Sujatta M, Karsch KR. First clinical experience with low molecular weight heparin LU 47311 (reviparin) for prevention of restenosis after percutaneous transluminal coronary angioplasty. Semin Thromb Hemost 1993;19:155-9.
22. 22. Serruys PW, De Jaegere P, Kiemeneij F, Macaya C, Rutsch W. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-98.
23. 23. Faxon DP. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR study, a multicenter, double-blind, placebo-controlled trial of cilazapril. J Am Coll Cardiol 1995;25:362-9.
24. 24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
25. 25. Clowes AW, Karnowsky MJ. Suppression by heparin of smooth muscle cell proliferation in injured arteries. Nature 1977;265:625-6.
26. 26. Castello J, Cochran D, Karnovsky M. Effect of heparin on vascular smooth muscle cell. I. Cell metabolism. J Cell Physiol 1985;124:21-8.
27. 27. Majesky MW, Schwartz SM, Clowes MM, Clowes AW. Heparin regulates smooth muscle S phase entry in the injured rat carotid artery. Circ Res 1987;61:296-300.
28. 28. Buchwald AB, Unterberg C, Nebendahl K, Grone HJ, Wiegand V. Low-molecular-weight-heparin (enoxiparin) reduces neointimal proliferation after coronary stent implantation in hypercholesterolemic minipigs. Circulation 1992;86:531-7.
29. 29. Guyton J, Rosenberg R, Clowes A, Karnovsky M. Inhibition of rat arterial smooth muscle cell proliferation by heparin: in vitro studies with anticoagulant and anticoagulant heparin. Circ Res 1980;46:625-34.
30. 30. Jeske W, Lojewski B, Walenga JM, Hoppenstaeadt D, Ahsan A, Farced J. Biochemical and pharmacologic profile of low molecular weight heparin (LU 47311, Clivarin). Semin Thrombosis Hemost 1993;19:229-40.
31. 31. Ellis SG, Roubin GS, Wilentz J, Douglas JS Jr, King SB III. Effect of 18 to 24 hour heparin administration for prevention of restenosis after uncomplicated coronary angioplasty. Am Heart J 1989;117:777-82.
32. 32. Schmidt T, Tebbe U, Brune SS, Schrader J, Kreuzer H. Pharmacological therapy after coronary angioplasty. Klin Wochenschr 1990;68:294-5.
33. 33. Kehmann KG, Doria RJ, Feuer JM, Hoang DT. Paradoxical increase in restenosis rate with chronic heparin use: final results of a randomized trial [abstract]. J Am Coll Cardiol 1991;17 Suppl:181A.
34. 34. Faxon DP, Spiro TE, Minor S, et al., and the ERA Investigators. Low molecular weight heparin in prevention of restenosis after angioplasty. Circulcation 1994;90:908-14.
35. 35. Simsons M, Edelman R, DeKeyser JL, Langer R, Rosenberg RD. Antisense c-myb oligonucleotides inhibit intimal arterial smooth muscle cell accumulation in vivo. Nature 1992;359:67-70.
36. 36. Goldman B, Blanke H, Wolinsky H. Influence of pressure on permeability of normal and diseased muscular arteries to horse radish peroxidase. Atherosclerosis 1987;65:215-25.
37. 37. Wilensky RL, March KL, Hathaway DR. Direct intraarterial wall injection of microparticles via a catheter: a potential drug delivery strategy following angioplasty. Am Heart J 1991;122:1136-40.
38. 38. Serruys P, De Jaegere P, Kiemeneij F. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
39. 39. Chan P, Patel M, Betteridge L. et al. Abnormal growth regulation of vascular smooth muscle cells by heparin in patients with restenosis. Lancet 1993;341: 341-2.
40. 40. Geary RL, Koyama N, Wang TW, Vergel S, Clowes AW. Failure of heparin to inhibit intimal hyperplasia in injured baboon arteries: the role of heparin-sensitive and -insensitive pathways in the stimulation of smooth muscle cell migration and proliferation. Circulation 1995;91:2972-81.
41. 41. Rutsch W, Simon R, Bode C, et al. Recombinant hirudin as an adjunctive therapy to PTCA.
42. 42. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330:956-61.